Clot Extraction With the FlowTriever Device in Acute Massive Pulmonary Embolism

2016 ◽  
Vol 31 (10) ◽  
pp. 676-679 ◽  
Author(s):  
Aaron Samuel Weinberg ◽  
Suhail Dohad ◽  
Danny Ramzy ◽  
Hooman Madyoon ◽  
Victor F. Tapson
Keyword(s):  
Pulmonary Embolism ◽  
Case Report ◽  
Thrombolytic Therapy ◽  
Clinical Guidelines ◽  
Treatment Options ◽  
Massive Pulmonary Embolism ◽  
Novel Device ◽  
First Case ◽  
Systemic Thrombolytic Therapy ◽  
Acute Pe

Clinical guidelines support the use of systemic thrombolytic therapy for acute massive pulmonary embolism (PE). When anticoagulation and thrombolysis fail or are contraindicated, options become limited. We report an acute PE case in which treatment options were limited, and a novel device, the FlowTriever (Inari Medical, Irvine, California), was successfully used. This is the first case report of the use of this device that we are aware of.

Massive pulmonary embolism in a young boy with T-cell leukaemia

2014 ◽  
Vol 34 (03) ◽  
pp. 233-236
Author(s):  
C. Martin ◽  
F. Alt ◽  
A. Wingerter ◽  
G. Staatz ◽  
H. Schinzel ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Acute Pulmonary Embolism ◽  
Recombinant Tissue Plasminogen Activator ◽  
Massive Pulmonary Embolism ◽  
Bleeding Complications ◽  
Cell Leukaemia ◽  
Malignant Diseases ◽  
Systemic Thrombolytic Therapy ◽  
Tissue Plasminogen

SummaryAcute pulmonary embolism (PE) is a serious complication in association with malignant diseases. We describe the successful treatment of PE applying a systemic thrombolytic therapy in a 4-year-old boy with acute lymphoblastic leukaemia.The thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) 0.1 mg/ kg bodyweight per hour for six hours was continued for six days without important side effects. In particular no bleeding complications were observed. Computed tomography with contrast revealed a remarkable regression of the central PE. Without further delays the chemotherapy was resumed.

Role of rheolytic thrombectomy in massive pulmonary embolism with contraindication to systemic thrombolytic therapy

2010 ◽  
Vol 5 (6) ◽  
pp. 716-721 ◽  
Author(s):  
Dabit Arzamendi ◽  
Luc Bilodeau ◽  
Reda Ibrahim ◽  
Stephane Noble ◽  
Richard Gallo ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Massive Pulmonary Embolism ◽  
Systemic Thrombolytic Therapy ◽  
Rheolytic Thrombectomy

Pulmonary Embolism and Postoperative Care

2020 ◽  
pp. 59-72
Author(s):  
Daniel Haines ◽  
Joel Grigsby
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Right Ventricular ◽  
Treatment Options ◽  
Right Ventricular Dysfunction ◽  
Myocardial Necrosis ◽  
Systemic Thrombolysis ◽  
Catheter Directed Thrombolysis ◽  
The Stability ◽  
Acute Pe

This chapter assesses pulmonary embolism (PE), which is an obstruction of the pulmonary circulation by an occlusive material. The material may be thrombus, air, tumor, or fat. PE are classified as acute, subacute, or chronic; but they can be further classified into massive and submassive. Submassive PE is defined as an acute PE without systemic hypotension but with either right ventricular dysfunction or myocardial necrosis, while massive PE is defined as an acute PE with sustained shock. There are several strategies for treating PE depending on the stability of the patient and the location of the clot. Systemic thrombolysis, catheter-directed thrombolysis, and catheter-directed clot removal are all treatment options, if there are no contraindications. Bleeding risk is the largest contraindication for thrombolytic therapy. Meanwhile, surgical embolectomy is warranted for hemodynamically unstable patients as well as patients with contraindications to or who failed thrombolytic therapy and catheter-based approaches. Right ventricular failure is a serious complication following pulmonary embolectomy and is managed by a compilation of volume removal, inotropic support, pulmonary vasodilation, and mechanical support, if needed.

Sign in / Sign up

Export Citation Format

Share Document